ZBiotics, the trailblazers of genetically engineered probiotics, has announced the successful close of a $12M Series A funding round led by Spring Tide Capital. The round, which was oversubscribed, saw participation from Access Capital, Seamless Capital, Goat Rodeo Capital, and Seaside Ventures. The infusion of capital will be pivotal in scaling the company’s operations to meet increasing consumer demand, expand retail presence, and advance research and development to bring new probiotic products to market that tackle the emerging biological challenges of modern life.

Founded and driven by a team of Ph.D. scientists dedicated to enhancing the human body’s natural functions, ZBiotics is at the forefront of a new wave of genetic engineering—transparent, responsible, and designed with consumers in mind. By harnessing cutting-edge biotechnology, ZBiotics empowers individuals to take charge of their health with genetically engineered probiotics tailored to address specific, real-world problems. Their flagship product, the Pre-Alcohol Probiotic Drink, exemplifies this mission by mimicking the liver’s function to break down acetaldehyde, the toxic byproduct of alcohol, thereby helping consumers feel better the day after drinking.

“Genetic engineering allows us to create entirely new products that meet real consumer needs, and the growing interest in our technology and brand is a testament to that,” said Zack Abbott, Ph.D., Co-Founder and CEO of ZBiotics. “In a market that demands genuine solutions, our commitment to being a proudly GMO company focused on transparency resonates with consumers, driving the momentum behind ZBiotics. With this new funding, we're poised to meet demand and expand our product line beyond our initial offering.”

ZBiotics is charting a new course by combining biotechnology with consumer products to solve problems that, until now, only had temporary fixes. The company's mission to improve human health through modern biotechnology is evident in its innovative approach to creating sustainable, effective solutions that are only possible through genetic engineering.

“ZBiotics has seen incredible growth, doubling sales annually and selling over 5 million units since the launch of their first product, achieving company-wide profitability in 2023,” remarked Adam Ramada, co-managing partner of Spring Tide Capital. “We’re excited to support the ZBiotics team as they expand their revolutionary probiotic platform to tackle more everyday health challenges.”

The funds from the Series A round will enable ZBiotics to further develop and introduce additional use-case probiotics, leveraging the same technology behind their Pre-Alcohol Probiotic Drink to create new solutions for consumers focused on various aspects of their health. Alongside their flagship product, ZBiotics is set to launch a second product in the coming weeks, emphasizing enhancing microbial diversity in the gut and its related benefits. The company's research and development efforts are also exploring new products that address concerns like sleep, vaginal health, and athletic performance. Moreover, the funding will support ZBiotics' entrance into physical retail spaces, aligning with the company’s long-term goal of making “proudly GMO” products more accessible to consumers who stand to benefit from their groundbreaking solutions.